Try Alerts Free   |   Login
Health Care › BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

KYMR Price Correlated With Financials For Kymera Therapeutics

Free historical financial statements for Kymera Therapeutics Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 7 quarters since 2020. Compare with KYMR stock chart to see long term trends.

KYMR Stock Compared to Quarterly

KYMR Income Statement

Revenue, Net:9622000
Revenue Per Share:0.186
Selling, General & Admin Expense:10611000
Research & Development Expense:35944000
Total Operating Expenses:46555000
Operating Income:-36933000
Income Taxes:0
Net Income:-36684000
Earnings Per Share, Basic:-0.71
Shares Outstanding, Basic Avg:51724179

KYMR Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:687000
Net Cash from Operations:-40295000
Net Cash from Operations Per Share:-0.779
Net Cash from Financing Activities:185000
Property, Plant & Equipment Purchases:482000
Net Cash from Investing Activities:25863000
Net Change in Cash & Equivalents:-14247000

KYMR Balance Sheet

Cash and Cash Equivalents:39845000
Total Current Assets:431382000
Property, Plant & Equipment, Net:11759000
Total Assets:563060000
Accounts Payable:2567000
Total Short-Term Liabilities:88339000
Total Liabilities:134340000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
BVF PARTNERS L P/IL   Director
250,000 sh at $19
$4,865,365
Buy

Data imported from Kymera Therapeutics Inc. SEC filings. Check original filings before making any investment decision.